BMS-790052 Daclatasvir Powder - Product

Other Specification : Daclatasvir 1009119-64-5 BMS-790052 Hepatitis C Treatment Raw Material Drug White Quick Detail - - - - Name: | Daclatasvir (BMS-790052) | CAS No.: | 1009119-64-5 | Formula: | C40H50N8O6 | Molecular Weight: | 738.875 | Synonyms: | BMS-790052; | Density: | 1.25 G/cm3 | Boiling Point: | 1071.239 C At 760 MmHg | Flash Point: | 601.664 C | Appearance: | White Powder | - - - - DaclatasvirDescription Daclatasvir (USAN, Formerly BMS-790052, Trade Name Daklinza) Is A Drug For The Treatment Of Hepatitis C (HCV). Daclatasvir Has Been Tested In Combination Regimens With Pegylated Interferon And Ribavirin, As Well As With Other Direct-acting Antiviral Agents Including Asunaprevir And Sofosbuvir. It Is On The World Health Organization's List Of Essential Medicines, A List Of The Most Important Medications Needed In A Basic Health System. There Has Been Significant Controversy Over The Price That Bristol-Myers Squibb Has Chosen To Charge For The Drug. DaclatasvirUses - - - - Uses 1 | Daclatasvir (brand Name Daklinza) Is A New Medication Used To Treat Hepatitis C. | Uses 2 | Daclatasvir Is An Antiviral Medicine That Prevents Hepatitis C Virus (HCV) From Multiplying In Your Body. | Uses 3 | Daclatasvir Is Used To Treat Genotype 3 Chronic Hepatitis C In Adults Without Cirrhosis. This Medicine Is Given Together With Another Drug Called Sofosbuvir. | Uses 4 | For Others, Daclatasvir Can Shorten Treatment When Added To Pegylated Interferon And Ribavirin. Successful Treatment Reduces The Risk Of Long-term Complications Of Hepatitis C Such As Liver Cancer Or Needing A Liver Transplant. | - - - - Daclatasvir Work # # Daclatasvir Is One Of The New Direct-acting Antiviral Drugs That Target Different Steps Of The Hepatitis C Virus (HCV) Lifecycle. It Is The First-eve

View Profile